Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a deal valued at $2.9 billion, marking a significant expansion of Neurocrine's endocrinology and rare-disease portfolio. The acquisition centers on Soleno's lead asset, a treatment for Prader-Willi syndrome (PWS), a rare genetic disorder affecting approximately 10,000 people in the United States. PWS is characterized by relentless, compulsive hunger that can lead to severe obesity, diabetes, and life-threatening complications such as stomach rupture. This transaction represents the first approved treatment specifically targeting this condition. The deal highlights continued activity in the biotech sector, with Neurocrine securing a unique therapeutic option to address a critical unmet medical need. Both companies' stock prices saw positive movement following the announcement.
Wire timeline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a deal valued at $2.9 billion, marking a significant expansion of Neurocrine's endocrinology and rare-disease portfolio. The acquisition centers on Soleno's lead asset, a treatment for Prader-Willi syndrome (PWS), a rare genetic disorder affecting approximately 10,000 people in the United States. PWS is characterized by relentless, compulsive hunger that can lead to severe obesity, diabetes, and life-threatening complications such as stomach rupture. This transaction represents the first approved treatment specifically targeting this condition. The deal highlights continued activity in the biotech sector, with Neurocrine securing a unique therapeutic option to address a critical unmet medical need. Both companies' stock prices saw positive movement following the announcement.
Technology - WSJ.com